You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Targeted DNA extraction for Tuberculosis PCR from sputum

    SBC: PHRIXUS PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Present diagnostic methods for active Tuberculosis are inadequate. Acid fast staining and microscopy of sputum is insensitive, particularly in advanced AIDS when atypical smear- negative presentations increase. Mycobacterial culture is the gold standard but is technically demanding and time consuming (i.e., weeks), limiting clinical utility. Novel serologic tes ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  2. Targeted Imaging Mass Spectroscopy for Biomarker Detection in Human Tissues

    SBC: PROVIA BIOLOGICS LIMITED LIABILITY COMPANY            Topic: NCI

    DESCRIPTION (provided by applicant): Biomarkers are measured in patient tissue biopsies to refine diagnosis, and to guide therapy. For a patient, this means receiving the therapy or drug most likely to work while avoiding the expense and toxic side effectsof alternatives. In pathology, a long-standing problem is that the most accurate methods for biomarker detection in tissues require extraction a ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Targeted Nanoparticles of Bismuth Organo Complexes for Spectral CT Imaging of Cor

    SBC: Ocean Nanotech LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Chest pain in patients presenting to the emergency department ED present a clinical dilemma transfer for emergent coronary revascularization admit overnight for cardiac telemetry and stress testing or discharge home with medical follow up In this proposal we hypothesize that a novel thrombus specific Spectral Computed Tomography Multicolored CT nanopar ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Targeted Polymeric Combination Delivery for Treatment of Ovarian Cancer

    SBC: THERATARGET, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This Phase I proposal details the rationale and the research plan for the synthesis and characterization of a polymeric delivery system that will deliver two anticancer drugs with diverse mechanisms of action simultaneously into ovarian cancer cells. The delivery system will be composed of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer as the backbone. It i ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Targeting alpha particle-emitting radionuclides to the nuclei of cancer cells

    SBC: ALPHAMED, INC            Topic: N/A

    DESCRIPTION (provided by applicant): This proposal outlines a body of research to evaluate the cytotoxicity and therapeutic efficacy of radiolabeled alpha-melanocyte stimulating hormone (a-MSH) peptide analogs that target a-particle emitting radioisotopes to the nuclei of melanoma cells. The selective targeting of alpha-particle emitting radioisotopes for cancer therapy is emerging as an exciting ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  6. TARGETING AN ESSENTIAL METHYLASE IN PATHOGENIC BACTERIA

    SBC: IBIS BIOSCIENCES, INC.            Topic: N/A

    N/A

    STTR Phase I 1998 Department of Health and Human Services
  7. Targeting a non-opioid signaling pathway to reverse opioid-induced respiratory depression

    SBC: Olfa Thera, Inc.            Topic: NIDA

    Project Summary/AbstractThe opioid epidemic is a growing public health crisis with dramatic increase in overdose deaths caused by potent opioids like fentanyl. Currently, the standard treatment for opioid-induced respiratory depression is naloxone, a µ-opioid receptor antagonist. However, naloxone is less effective against potent synthetic opioids like fentanyl and induces withdrawal in chronic o ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Targeting cadherin-11 in pancreatic cancer

    SBC: Diviner Therapeutics LLC            Topic: 102

    Pancreatic cancer is soon to be the second leading cause of cancer-related death with an overall median survival of 8 - 11 months. For 70% of patients, systemic chemotherapy is the only option and this mainly relieves the symptoms and/or slightly extends survival, rather than cures the patients. One of the hallmarks of PDAC is extensive fibrosis that comprises up to 80% of the tumor. Cancer-associ ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Targeting C/EBP-beta Phosphorylation for the Treatment of Lung Fibrosis

    SBC: XFIBRA, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Activation of lung myofibroblasts LMF is responsible for the development of lung fibrosis in chronic lung diseases of all causes and remarkably LMF clearance by apoptosis may prevent development of lung fibrosis and lung injury and possibly allow recovery from reversal of lung fibrosis There is full agreement among tissue fibrosis experts that inhibiting o ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting Covid-19 with a Therapeutic Interfering Particle

    SBC: ALEPH THERAPEUTICS INC            Topic: NIAID

    SUMMARYThe Covid-19 pandemic caused by Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) is currently the most important public health crisis in the world. Given the unprecedented scope of this disease, it is critical to explore novel strategies to mitigate this crisis. Aleph Therapeutics and UCSF have jointly developed eTIP1, a Therapeutic Interfering Particle. eTIP1 was developed under a DARPA ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government